New Delhi, July 29 -- Danish drug-making company Novo Nordisk has named Mazir Mike Doustdar as its new Chief Executive Officer on Tuesday.

The company, known for its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, made this announcement alongside lowering its earnings forecasts again.

Doustdar, an executive in the company for over three decades, has been given the responsibility to tackle "recent market challenges".

Maziar Mike Doustdar has been working with Novo Nordisk since 1992. He started working in the company as an office clerk. However, he quickly rose through the ranks and became a key figure in the company's core business.

He holds a BA in International Business from Webster University, Vienna (1994), and late...